Investigational two-drug combination · Fact sheet
Tesomet
Also known as Tesofensine + metoprolol
Tesomet combines tesofensine and metoprolol. A small hypothalamic-obesity trial found weight reduction, but this is not an established general-obesity regimen or proof that metoprolol removes all tesofensine risks.
What is Tesomet?
Tesofensine inhibits monoamine reuptake; metoprolol is a beta blocker included to moderate cardiovascular effects.
The combination is a small-molecule treatment, not a peptide blend.
Benefits & claims
Interest centers on obesity after hypothalamic injury, a specific clinical problem distinct from ordinary weight-management populations.
What the evidence supports
- Tesomet produced a 6.3-percentage-point greater mean weight reduction than placebo, with considerable uncertainty.
- No significant between-group blood-pressure or heart-rate difference was observed, but the trial was small.
- The hypothalamic-obesity result cannot establish general-obesity or self-use benefits.
Research areas
- Hypothalamic obesity
- Appetite and body weight
Dosage & frequency
Human study contextThe 24-week hypothalamic-obesity study supplies a specific combination exposure, not a general weight-loss schedule.
Tesomet randomized trial (NCT03845075)
21 adults with hypothalamic obesity following hypothalamic injury
- Amount
- Tesofensine 0.5 mg plus metoprolol 50 mg
- Frequency
- Daily for 24 weeks
- Route studied or labeled
- Oral study treatment
Participants also received diet and lifestyle counseling. Safety was the primary endpoint, weight outcomes were secondary, and one treatment-related serious anxiety event occurred. This summary does not reproduce the full eligibility or monitoring protocol.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Tesofensine inhibits monoamine reuptake; metoprolol is a beta blocker included to moderate cardiovascular effects.
Formulation differences
- The combination is a small-molecule treatment, not a peptide blend.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Larger controlled efficacy estimates
- Long-term cardiovascular and psychiatric safety
- Benefit in other obesity populations
Side effects & risks
- Sleep disturbances, dry mouth and headache were reported.
- One participant had worsening pre-existing anxiety classified as a treatment-related serious adverse event and stopped treatment.
- Metoprolol introduces its own cardiovascular and drug-interaction considerations.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceThe randomized 24-week study enrolled 21 adults. Its main focus was safety, and weight outcomes were secondary; the sample is too small for a broad efficacy or cardiovascular-safety conclusion.
Studies
21-person study with weight, safety and anxiety findings.
Separate 203-person general-obesity trial; not a Tesomet regimen.
Official record for the hypothalamic-obesity study.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Tesomet has no FDA-approved weight-management indication. Approval of metoprolol for other uses does not approve this combination.
Phase 2 research; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Larger controlled efficacy estimates
- Long-term cardiovascular and psychiatric safety
- Benefit in other obesity populations
Summary
The hypothalamic-obesity result cannot establish general-obesity or self-use benefits.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedTesomet randomized hypothalamic-obesity trial
21-person study with weight, safety and anxiety findings.
- pubmedTesofensine monotherapy trial
Separate 203-person general-obesity trial; not a Tesomet regimen.